HK Stock Market Move | Light industry Siasun Robot & Automation enterprise (06871) fell more than 11% on the day after going public, following a more than 76% rise in the previous day.
The day after Yifei Technology (06871) went public, it fell by over 11%. As of the end of trading, it dropped by 11.63%, closing at 47.5 Hong Kong dollars, with a trading volume of 1.28 billion Hong Kong dollars.
On the day after going public, the stock fell by more than 11%, closing at 47.5 Hong Kong dollars, with a trading volume of 1.28 billion Hong Kong dollars.
Public information shows that the company focuses on the design, research and development, manufacturing, and commercialization of industrial Siasun Robot&Automation, providing comprehensive solutions for Siasun Robot&Automation and deepening its presence in light industry applications. According to a report by Frost & Sullivan, based on 2025 revenue projections, the company ranks fourth among domestic suppliers of industrial Siasun Robot&Automation and related solutions focused on light industry applications in China.
Financially speaking, the company is currently experiencing continuous losses. Adjusted net losses for 2023 to 2025 are projected to be approximately 106 million, 52.325 million, and 86.637 million yuan, respectively. It is worth noting that, according to the company's allocation results announcement, the public offering portion received a subscription rate of about 14,855.4 times, far surpassing last year's ChiNext new stock Gold Leaf International's historical record of 11,464 times, officially topping the list of oversubscribed new stocks on the Hong Kong Stock Exchange.
Related Articles

COUNTRY GARDEN (02007) issued 122 million shares of zero-interest mandatory convertible bonds for conversion.

In the first quarter of the company, the profit attributable to owners decreased by 68.1% to HK$2.9 million.

Zhejiang Tianyu Pharmaceutical (300702.SZ): Gliclazide tablets obtained drug registration certificate
COUNTRY GARDEN (02007) issued 122 million shares of zero-interest mandatory convertible bonds for conversion.

In the first quarter of the company, the profit attributable to owners decreased by 68.1% to HK$2.9 million.

Zhejiang Tianyu Pharmaceutical (300702.SZ): Gliclazide tablets obtained drug registration certificate






